Figure 5
The combination of atorvastatin and sorafenib enhances anti-tumour activities in vivo.
(A) Relative tumour volume of HepG2 xenograft tumour in control, atorvastatin, sorafenib and combination groups. (B) Tumour growth inhibition in control, atorvastatin, sorafenib and combination groups. Representative tumours in each group, tumour weight, inhibition ratio and T/C values. (C) Phosphorylation level of YAP-S127 in sorafenib- and/or atorvastatin-treated xenograft tumour tissues. (D) Immunofluorescence analysis of YAP in xenograft tumours from sorafenib, atorvastatin or combination groups. Scale bars, (up) 50 μm, (bottom) 20 μm. (E) Quantification of the nuclear YAP population from the immunofluorescence staining of YAP of the xenograft tumours in each group.
